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548Objectives:Cardiogenic shock after cardiac surgery is accompanied by a high mortality rate. Early institution of
hemodynamic support with a versatile, easy to insert left ventricular assist device might help bridge patients to
recovery or to the next therapy, and improve the outcomes.
Methods: Patients developing cardiogenic shock or low cardiac output syndrome after being weaned off cardio-
pulmonary bypass were enrolled in a prospective single-arm feasibility study (RECOVER I). The primary safety
endpoint was the frequency of major adverse events (death, stroke) at 30 days or discharge, whichever was lon-
ger. The primary efficacy endpoint was survival of the patient to implementation of the next therapy, which in-
cluded recovery at 30 days after device removal and bridge-to-other-therapy.
Results: Sixteen patients provided informed consent and were enrolled in the study. Hemodynamics improved
immediately after the initiation of mechanical support: cardiac index, 1.65 versus 2.7 L/min/m2 (P ¼ .0001);
mean arterial pressure, 71.4 versus 83.1 mm Hg (P ¼ .01); and pulmonary artery diastolic pressure, 28.0 versus
19.8 mmHg (P<.0001). The pump provided an average of 4.0 0.6 L/min of flow for an average duration of 3.7
 2.9 days (range, 1.7–12.6). The primary safety endpoint occurred in 2 patients (13%; 1 stroke and 1 death).
For the primary efficacy endpoint, recovery of the native heart function was obtained in 93% of the patients dis-
charged, with bridge-to-other-therapy in 7%. Survival to 30 days, 3 months, and 1 year was 94%, 81%, and
75%, respectively.
Conclusions: The use of the Impella 5.0/left direct device is safe and feasible in patients presenting with post-
cardiotomy cardiogenic shock. The device was rapidly inserted, enabled early support, and yielded favorable
outcomes. (J Thorac Cardiovasc Surg 2013;145:548-54)Patients with postcardiotomy cardiogenic shock (PCCS)
continue to have poor outcomes. Despite recent advances
in surgical techniques and aggressive therapy with in-
creased inotropic support and counterpulsation intra-aortic
balloon pumps (IABPs), the overall mortality is frustrat-
ingly high.1,2 For those patients refractory to inotropic
and/or IABP therapy, studies have shown that early
ventricular assist device (VAD) implantation improves
survival.3-5 However, the use of current surgical VADs fore Department of Cardiac Surgery,a University of Maryland Baltimore, Balti-
Md; Department of Cardiothoracic Surgery,b Robert Wood Johnson Univer-
ospital, New Brunswick, NJ; Department of Cardiothoracic Surgery,c
nau Medical Science Hospital, Wynnewood, Pa; Department of Cardiotho-
Surgery,d Penn State Hershey Heart and Vascular Institute, Penn State Milton
rshey Medical Center, Hershey, Pa; Department of Surgery,e New York-Pres-
an Hospital/Columbia Milstein Hospital, New York, NY; and Department of
othoracic Surgery,f Tex Heart Institute, St. Luke’s Episcopal Hospital,
ton, Tex.
nd Drug Administration Investigational Device Exemption (IDE No.
202) was obtained by the study sponsor (Abiomed, Danvers, Mass).
res: Authors have nothing to disclose with regard to commercial support.
d for publication Nov 18, 2011; revisions received Dec 30, 2011; accepted for
ation Jan 24, 2012; available ahead of print March 12, 2012.
for reprints: Bartley P. Griffith, MD, Department of Cardiac Surgery, Univer-
f Maryland Baltimore, 22 South Greene Street, N4W94, Baltimore, MD
(E-mail: BGRIFFITH@smail.umaryland.edu).
23/$36.00
ht 2013 Published by Elsevier Inc. on behalf of The American Association
acic Surgery
016/j.jtcvs.2012.01.067
The Journal of Thoracic and Cardiovascular SurgPCCS remains limited, because they require significant
incremental surgery and highly trained operative and
postoperative teams. Moreover, no guidelines have been
established for patient selection for the early use of VADs
in this setting.
The Impella 5.0/left direct (LD) (Abiomed,Danvers,MA)
is a minimally invasive, 21F, rotary blood pumpmounted on
a 9F driveline/bearing purge delivery catheter (Figure 1).
The pump is positioned retrogradely in the left ventricle
(LV) across the aortic valve.When in function, the pump as-
pirates the blood from the LVand expels it into the ascending
aorta, providing up to 5 L/min of forward flow into the gen-
eral circulation. The pump actively unloads the LV and in-
creases the coronary perfusion, thereby improving the
myocardium oxygen supply/demand ratio.6,7 Considering
its relative ease of insertion and potential beneficial
hemodynamic effect, the Impella 5.0/LD might fill
a technology gap for perioperative patients who require
early and potent circulatory support to restore normal
cardiac function or to bridge them to the next therapy.
The RECOVER I study was a prospective, single-arm,
clinical trial designed under US Food and Drug Administra-
tion guidance to investigate, at a maximum of 7 sites, the
safety and feasibility of the Impella 5.0/LD in up to 20 pa-
tients experiencing cardiogenic shock (CS) or low cardiac
output syndrome after cardiac surgery.ery c February 2013
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
CS ¼ cardiogenic shock
IABP ¼ intra-aortic balloon pump
LD ¼ left direct
LV ¼ left ventricle
LVAD ¼ left ventricular assist device
PCCS ¼ postcardiotomy cardiogenic shock
VAD ¼ ventricular assist device
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Study Population
Eligible patients were those with low cardiac output (cardiac index,
1.3 but 2.2 L/min/m2) and elevated filling pressures (pulmonary capil-
lary wedge pressure, 20 but 30 mm Hg or pulmonary artery diastolic
pressure 25 but 35 mm Hg) after weaning from cardiopulmonary by-
pass (CPB) despite stable infusion of 1 high-dose inotrope or 2 medium-
dose inotropes (considered medium and high dose for epinephrine<0.03
and 0.03 mg/kg/min, respectively, for 15 minutes; for dobutamine and
dopamine<5 and5 mg/kg/min, respectively, for15 minutes; and milri-
none<0.3 and 0.3 mg/kg/min, respectively, for 120 minutes). The ex-
clusion criteria were age younger than 18 or older than 75 years,
elevated blood urea nitrogen of 100mg/dL ormore, renal failure (creatinine
 3.5 mg/dL), hepatic dysfunction (total bilirubin  5 mg/dL), and the
presence of any cardiac assist device other than IABP. Additional exclusion
criteria were right ventricular failure (defined as central venous pressure–
pulmonary capillary wedge pressure 10 mm Hg or central venous pres-
sure–pulmonary artery diastolic pressure 10 mm Hg or cardiac ascites),
evidence of any vascular disease that would preclude placement of the
peripheral device, and evidence of left ventricular or right ventricular
thrombus. The remaining exclusion criteria were aortic insufficiency
(2þ echocardiographic), aortic valve stenosis (valve orifice area  1.5
cm2), the presence of a mechanical aortic valve, obstructive or hypertrophic
cardiomyopathy, uncorrected ventricular or atrial septal defect, patent fora-
men ovale, mechanical manifestation of acute myocardial infarction, disor-
der causing fragility of blood cells or hemolysis, a cardiopulmonary
resuscitativemaneuver lasting longer than 15minuteswithin 24hours before
pump implantation, active systemic infection, sustained or nonsustained
ventricular tachycardia or ventricular fibrillation unresponsive to medical
therapy, and participation in another investigational drug or device trial.
Device and Procedures
The device was inserted through a direct or peripheral approach. When
a direct insertion, the device was inserted through a 10-mm vascular graft
sewn to the ascending aorta and advanced across the aortic valve into the
LV. When a peripheral insertion, the device was introduced through a fem-
oral artery cut down. Using a guidewire, the device was then advanced ret-
rogradely under fluoroscopy or transesophageal echocardiography
guidance across the aortic valve and positioned in the LV. When the chest
tube drainage decreased to less than 100 mL/hr, a continuous intravenous
infusion of heparin was recommended to achieve a partial thromboplastin
time of 40 to 50 seconds.
Per protocol, the recommended duration of support was up to 7 days.
The timing of device removal was left to the discretion of the physician.
For patients in whom hemodynamic stability was achieved, weaning was
started in a stepwise fashion by decreasing the pump speed. Once the speed
was reduced to the minimal level of support and well tolerated for about 2
hours, the patient returned to the operating room for device removal. In the
case of direct insertion, the pump was retracted into the vascular graft
sleeve that was oversewn and then removed. Peripherally placed devicesThe Journal of Thoracic and Cawere retrieved from the femoral insertion site either in the operating
room or at the bedside.
Study Procedures
Transthoracic echocardiography was performed before and after pump
insertion, at pump removal, at 30 days or at discharge, and 3 months after
the procedure. The echocardiographic studies were analyzed by an inde-
pendent core laboratory (Duke University Clinical Research Institute
Echocardiographic Laboratory). Hemodynamic measurements were re-
corded before and during support using a Swan-Ganz catheter for continu-
ous cardiac output monitoring. The heart rate and blood pressure were
monitored after pump and central catheter removal. Serial blood sampling
was obtained before, during, and after support for cardiac enzymes, plasma
free hemoglobin, biochemistry, blood gases, and hematologic features. If
practical, a neurologic assessment was performed before insertion, daily
until hospital discharge, and at 30 days and 3 months.
The institutional review board of each center approved the study. When
possible, written informed consent was obtained from each patient preop-
eratively if the patient was considered to be a high-risk candidate for sur-
gery. Alternatively, written informed consent was obtained from the next
of kin during surgery in emergency situations according to the protocol.
The Clinical Trial Registration Information unique identifier was
NCT00596726.
Study data were collected prospectively by research coordinators on
case report forms and verified against source documentation by indepen-
dent trial monitors. An independent thoracic surgeon with expertise in cir-
culatory support adjudicated all adverse events.
Study Endpoints
The primary safety endpoint was the frequency of major adverse events,
defined as death or stroke at 30 days or discharge, whichever was longer.
Device malfunction and other complications were included in the adverse
event analysis. The primary efficacy endpoint was survival of the patient to
the implementation of the next therapy, which included recovery, defined as
30-day survival after removal or hospital discharge (whichever was longer)
with no other mechanical support or IABP, and bridge-to-other-therapy, de-
fined as survival to induction of anesthesia for surgery for cardiac trans-
plantation or placement of an implantable VAD. The secondary efficacy
endpoints included improved hemodynamics, device placement and tech-
nical success, time-to-recovery and reduction of inotropic/pressor support
compared with before device placement.
Statistical Analysis
The data are expressed as the mean  standard deviation, median
(range), or proportions, as appropriate. Univariate parametric analysis
was performed using a paired Student’s t test or analysis of variance with
repeated measures test. The Wilcoxon sign rank test was used for pair
wise nonparametric comparisons. The probability values were 2 tailed.
All investigators had access to study data.
RESULTS
Patient Characteristics
FromOctober 25, 2006, toMay 16, 2008, 16 patients pro-
vided written informed consent and enrolled at 4 US sites.
Thirteen were men and 3 were women, with a mean age
of 58.4 9 years (range, 43–72), and all were high-risk can-
didates for cardiac surgery (mean logistic European System
for Cardiac Operative Risk Evaluation, 34% 26%; range,
10–84%). They presented with poor left ventricular
function (mean ejection fraction, 23%  7%; range,
10–35%), and multiple co-morbidities, including heartrdiovascular Surgery c Volume 145, Number 2 549
FIGURE 1. Impella 5.0/LD left ventricular assist device (LVAD) (with
permission from Abiomed, Danvers, Mass).
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gina (44%), diabetes mellitus (38%), cardiogenic shock
(31%), and IABP (25%). Of the 16 patients, 11 (69%) un-
derwent coronary artery bypass grafting, 3 (19%) under-
went combined coronary artery bypass grafting and mitral
valve replacement surgery, 1 (6%) underwent mitral valve
replacement surgery, and 1 (6%) underwent heart trans-
plant surgery. Of the 16 patients, 11 experienced cardio-
genic shock within minutes after weaning off CPB: 2
patients within less than an hour, 2 patients within less
than 8 hours, and 1 patient within 24 hours.
Procedural Characteristics
The Impella devicewas inserted peripherally in 5 patients
(31%) and directly in 11 (69%). Device placement was
rated as ‘‘easy’’ for 75% of the cases and ‘‘acceptable’’
for 25%. The time of insertion was less than 5 minutes
for 1 patient (6%), less than 10 minutes in 6 (38%), longer
than 10 but less than 15 minutes in 6 (38%), and longer than
15 minutes in 3 patients (18%). The mean duration of cir-
culatory support was 3.7  2.9 days (range, 1.7–12.6),
and the mean pump flow during support was 4.0  0.6 L/
min at the average performance level of 7.7 set by the oper-
ator (performance level range, 0–9) and 2.54  0.9 L/min
during weaning. There were 2 device malfunctions, most
likely due to catheter kinking causing a failure of the purge
system for both pumps on days 2 and 3 after insertion. One
patient had a replacement device inserted, and the other pa-
tient had recovered and was scheduled for device removal
the day of the device malfunction. Both patients were alive
at the 1-year study visit. Removal of the Impella 5.0/LDwas
uneventful in all patients.550 The Journal of Thoracic and Cardiovascular SurgSafety Endpoint
The primary safety endpoint (the frequency of major ad-
verse events [death or stroke] at 30 days or discharge,
whicheverwas longer) occurred in 2 patients (13%) (1 death
and 1 nonfatal stroke). The patient who died experienced
early complications during his heart transplant surgery,
with profuse bleeding, renal failure, and metabolic acidosis
that culminated in CS. Despite hemodynamic stabilization
after Impella implantation on postoperative day 1, the pa-
tient continued to deteriorate. Support was withdrawn on
3 days after device implantation, and the patient died
shortly thereafter. The patient who experienced a nonfatal
stroke was admitted in CS on IABP support and mechanical
assisted ventilation after failed percutaneous coronary inter-
vention. This patient underwent emergent coronary artery
bypass grafting followed by hemodynamic support with
the Impella 5.0 left ventricular assist device (LVAD).
Shortly afterward, the patient started showing signs of right
heart failure andwas subsequently supportedwith a Levitro-
nix right VAD. After removal of the devices, a clinical ex-
amination was possible and raised concerns about the
patient’s neurologic status. A computed tomography scan
revealed bilateral multiple cerebral ischemic infarcts. The
investigators were unable to determine the time of the onset
of the stroke.
One patient had hemolysis for which the relatedness to
the device could not be excluded. Six patients developed
sepsis. Of those 6 patients, 1 was supported with the device
for 12.6 days and the relatedness to the device could not be
ruled out (indwelling catheter). Eleven patients had contin-
uous respiratory support for longer than 48 hours after the
procedure, 7 patients developed bleeding requiring reoper-
ation (3 from the sternal wound, 1 with hemothorax in the
context of a coagulopathy, 1 with cardiac tamponade, 1
with a small chest cavity hematoma, and 1 with a remote
femoral artery vein patch rupture), 3 patients had renal fail-
ure, 1 patient had hepatic failure, and 1 patient had a remote
vascular injury (vein patch rupture). No cases of limb ische-
mia, vascular or cardiac perforation, thrombocytopenia,
ventricular fibrillation, or ventricular tachycardia were
reported.
There was no echocardiographic evidence of device-
related injury or dysfunction to the aortic or mitral valve,
papillary muscles, chordae, or ventricular cavity during or
after device use. At 30 days, a follow-up echocardiogram
was performed on 12 patients, and none had evidence of
valve dysfunction, or valve or ventricular, papillary muscle,
or chordate injury.
Efficacy Endpoint
The device was successfully inserted in 16 patients
(100%). Hemodynamic indexes improved immediately
once support was initiated. On average, the cardiac index
and mean arterial pressure increased from 1.6  0.4ery c February 2013
FIGURE 2. Average cardiac index and patient’s individual cardiac index
on support values reflect the average cardiac index measurements obtained
within the first 24 hours after device implantation.
FIGURE 3. Average mean arterial pressure (MAP) and patient’s individ-
ual MAP on support values reflect the average MAP measurements ob-
tained within the first 6 hours after device implantation.
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 12.5 mmHg to 83.1 7.5 mmHg (P¼ .01), respectively.
Unloading was shown in a reduction of the pulmonary ar-
tery diastolic pressure from 28.0  3.9 mm Hg to 19.8 
3.2 mm Hg (P<.0001). The patients’ hemodynamics im-
proved in conjunction with a decreased need for inotropic
medications (Figures 2, 3, and 4).
Survival at 30 days, 6 months, and 1 year was 94%, 81%,
and 75%, respectively. Of the 15 patients who survived to
30 days, 1 was successfully weaned off the Impella 5.0;
he withdrew consent the next day and was still alive at the
end of the study. Of the remaining patients, 13 (93%) recov-
ered their native heart function and 1 (7%) did not show any
evidence of ventricular recovery after 12.6 days of support.
On removal of the Impella LD, this patient underwent im-
plantation of an intracorporeal longer term LVAD (Jarvik
2000; Jarvik Heart, New York, NY) as a bridge to
transplantation.
DISCUSSION
Approximately 0.2% to 6% of patients undergoing cor-
onary or valvular cardiac procedures will develop PCCS.8
Increased inotropic and IABP support has been the most
widely used initial strategy to support these patients. How-
ever, a major drawback to this treatment approach resides in
the increased mortality associated with administration of
inotropes,9 and the improvement of hemodynamic parame-
ters and cardiac output10 is at the expense of increased my-
ocyte death and derangement in the functionality of the
remaining myocytes.11 In addition, the absence of active
left ventricular unloading and the requirement for a certain
residual level of left ventricular function with IABP mightThe Journal of Thoracic and Calimit the chance for cardiac recovery and potentially in-
crease the incidence of severe heart failure for the survivors.
For those patients refractory to inotropes and IABP sup-
port, VADs have been used as a last resort to save patients’
lives. Overall, the results in patients with PCCS have been
historically disappointing when heart recovery was
sought.12-14 More recently, early implantation of complete
mechanical circulatory assistance in the setting of PCCS
has improved survival. In a number of reports,15-18 an
improved outcome was obtained by active unloading of
the ventricle and rapid restoration of normal end-organ per-
fusion. Thus, we approached our patients with the assump-
tion that the early initiation of a minimally invasive potent
mechanical circulatory support device with direct unload-
ing capabilities would improve the outcomes compared
with those of a more conservative strategy of escalation in
vasoactive and inotropic medication, which has not proved
to improve the outcomes in these settings.5,10
The protocol was designed under Food and Drug Admin-
istration guidance and allowed enrollment of a maximum of
20 patients in the study. Recruiting these sick patients has
proved difficult and very challenging. The survival out-
comes were known because the data could not be blinded
in this open-label, single-arm trial. The study steering com-
mittee believed that enough clinical evidence was collected
with 16 patients to document the safety and feasibility of the
technology in consideration of the very favorable survival
outcomes. The consensus was that the additional time (ap-
proximately 8 months) required to enroll additional patients
was significant and that the information that could have
been collected from the remaining few patients could
not have changed the overall favorable safety trendsrdiovascular Surgery c Volume 145, Number 2 551
FIGURE 4. Average daily inotrope use.
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Administration and the study sponsor, the steering commit-
tee decided to end the study and submit the results.
The results of our study have demonstrated that the use of
the Impella enabled immediate restoration of hemodynam-
ics with a gradual reduction in the need of inotropic support.
Overall, 94% of patients survived to 30 days and, of those,
93% were weaned off mechanical support. The survival
outcomes were favorable in our study compared with those
for other VAD cohorts in postcardiotomy settings.19,20
Perhaps the early restoration of the hemodynamics
prevented the installation of irreversible end organ
dysfunction, which led to greater survival. In the present
study, Impella support was initiated promptly when the
patient experienced hemodynamic compromise despite
inotropic support. In routine practice, patients
experiencing PCCS or low cardiac output syndrome
would most likely receive an increased dose of inotropes
and an IABP before potent circulatory support with an
invasive VAD is considered. We were anxious to evaluate
this attractive one-of-a-kind, near-full-flow, yet catheter-
delivered, LVAD in a postcardiotomy setting. The rationale
for using the Impella short-term assist device as a ‘‘bridge-
to-decision’’ or ‘‘bridge-to-recovery’’ lies in the need for
a potent circulatory support system with low morbidity
that can be implanted quickly and managed easily in emer-
gent situations with catastrophic hemodynamic deteriora-
tion. It was also based on the belief that early
implantation of the pump was appropriate for this patient
population as confirmed by the poor patient hemodynamics
before pump insertion.
The minimum amount of inotropic support required by
the protocol to qualify for the study might have been552 The Journal of Thoracic and Cardiovascular Surgconservative. However, all our patients required a higher
dose than the protocol prespecified threshold of inotropic
support before enrollment with a mean cardiac index of
1.6  0.4 L/min/m2. At inclusion, the patients were receiv-
ing an average of 2 high doses of inotropes/pressors for at
least 15 minutes (dopamine or equivalent) to 120 minutes
(milrinone) without improvement of their hemodynamics.
The dose of inotropes (Figure 4) and pressors had to be in-
creased shortly afterward to an average of 3 inotropes/
pressors, given the continuous deterioration of the hemody-
namic status. After pump implantation, the hemodynamics
improved significantly, and the inotropes were weaned off
over time as the patient’s condition improved. Moreover,
the study investigators were asked to specify how they
would have treated the patients they enrolled if the Impella
were not available and the patient were to be treated outside
of the study. To this question and, in the investigators’ opin-
ion, 14 (88%) would have required a more invasive surgical
LVAD and 2 (12%) would have been treated with an IABP
with a high dose of 3 inotropes or more. Finally, they would
have considered delaying the escalation to a surgical LVAD,
given the additional morbidity ensued from the implanta-
tion procedure.
In the present study, bleeding events were within the
range of those reported in similar postcardiotomy studies,21
even though factors inherent to patient presentation and car-
diac surgery with CPB predisposed these patients to an in-
creased risk of microvascular bleeding requiring blood
transfusion and/or re-exploration surgery.22 No bleeding
events were related to the device itself. The sepsis rate in
our study was comparable to that observed in studies of pa-
tients in PCCS23 or CS requiring hemodynamic support.24
All sepsis events resolved with antibiotic treatment.ery c February 2013
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independent core laboratory, did not show any evidence of
structural damage to the heart during device use or in sub-
sequent follow-up. The aortic valve remained intact without
visible damage at all points, and there was no evidence of
left ventricular or proximal aorta structural damage. These
results are consistent with those of previous reports.16
The 2 device failures encountered during our study were
most likely due to a kink of the driveline that resulted in
blood entering the motor housing and leading to increased
resistance and, ultimately, pump failure. The manufacturer
has since released a kink-resistant catheter for the Impella
5.0/LD.
The Impella 5.0/LD is a versatile, effective, low-cost, and
significantly less-invasive LVAD able to directly unload the
LV and provide up to 5 L/min of flow to the general circu-
lation. Because implantation of the pump only requires
a low anticoagulation regimen, it is a very compelling alter-
native to surgical short-term VADs in the acute setting.
These advantages might lower the decision threshold for
the initiation of mechanical circulatory support to restore
the hemodynamics and prevent the aggravation of end-
organ dysfunction and potentially lead to improved out-
comes. For patients who do not recover their native heart
function, the device might provide time to adequately eval-
uate patients for potential long-term implantation of a dura-
ble VAD with a cost-effective bridge to transplant or
destination therapy strategy.
The protocol was designed so that a surgeon could place
the pump byway of the femoral artery and thus permanently
close the sternal wound. Alternatively, the device could be
placed directly by way of the ascending aorta, which re-
quired skin-only closure of the chest wound. In time, be-
cause of the expediency of avoiding femoral artery
exposure, the ease of echocardiographic-guided placement,
and concern about the potential for vascular injury (21F
pump) or potential ischemia, the surgeons came to prefer
the direct aortic approach.
In recent years, as the experience matured and the sur-
geons gained more confidence in implanting these
catheter-based pumps, the peripheral approach has become
the predominant implantation technique. The axillary ap-
proach appears to be preferable to the femoral approach, be-
cause it allows for early bed mobilization of the patient.17
Study Limitations
The major limitations of the present prospective, safety
and feasibility study were the lack of a control group and
the size and heterogeneity of the cohort enrolled, which
did not allow an easy statistical comparison of our results
with the results from other PCCS studies. Moreover, the ex-
trapolation of our results to a general postcardiotomy pa-
tient population is limited, because, in some cases,
cardiogenic shock occurred immediately after weaningThe Journal of Thoracic and Cafrom CPB and required rapid device implantation but in
a few other cases, it occurred several hours to up to 24 hours
after the patients were weaned off CPB.
CONCLUSIONS
The results from our study have shown that the use of the
Impella 5.0/LD system is safe and feasible and provides ex-
cellent hemodynamic support in the settings of PCCS or low
cardiac output syndrome. Compared with other surgical
short-term LVADs,25 the less-invasive implantation, ease
of use, lower cost, and favorable safety profile offered by
this technology make it a very compelling and convenient
alternative for both patients and surgeons.
We are grateful to the study investigators for their thoughtful
feedback during the preparation of this report and above all to
the patients who participated in our study to make this report
possible.
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